Antisense oligonucleotide treatments for psoriasis (Q34284377)

1 August 2017

1 reference

title

Antisense oligonucleotide treatments for psoriasis (English)

1 reference

1 August 2017

White PJ

1

1 reference

1 August 2017

Atley LM

series ordinal

2

1 reference

1 August 2017

Wraight CJ

series ordinal

3

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

Expert Opinion on Biological Therapy

1 August 2017

published in

1 reference

1 August 2017

volume

4

1 reference

1 August 2017

issue

1

1 reference

1 August 2017

page(s)

75-81

1 reference

Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Perspectives in antisense therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

An overview of progress in antisense therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Immunologic mechanisms in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Activated keratinocytes present bacterial-derived superantigens to T lymphocytes: relevance to psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Sequence dependence of C5-propynyl-dU,dC-phosphorothioate oligonucleotide inhibition of the human IGF-I receptor: mRNA, protein, and cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Expression of insulin-like growth factor binding protein-3 (IGFBP-3) in the psoriatic lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

A keratinocyte cell line synthesizes a predominant insulin-like growth factor-binding protein (IGFBP-3) that modulates insulin-like growth factor-I action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

21 January 2018

Coping with psoriasis

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Psoriasis causes as much disability as other major medical diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Psoriasis: maintenance of an intact monolayer basal cell differentiation compartment in spite of hyperproliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Antisense oligonucleotides inhibit vascular endothelial growth factor/vascular permeability factor expression in normal human epidermal keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Antisense Gene Inhibition by Oligonucleotides Containing C-5 Propyne Pyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Transdermal use of phosphorodiamidate morpholino oligomer AVI-4472 inhibits cytochrome P450 3A2 activity in male rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Transformed and immortalized cellular uptake of oligodeoxynucleoside phosphorothioates, 3'-alkylamino oligodeoxynucleotides, 2'-O-methyl oligoribonucleotides, oligodeoxynucleoside methylphosphonates, and peptide nucleic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Nonionic oligonucleotide analogs (Matagen) as anticodic agents in duplex and triplex formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Live confocal microscopy of oligonucleotide uptake by keratinocytes in human skin grafts on nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Targeted drug delivery to the skin and deeper tissues: role of physiology, solute structure and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

C-5 propyne-modified oligonucleotides penetrate the epidermis in psoriatic and not normal human skin after topical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Transport of oligonucleotides across natural and model membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Localization of a FITC-labeled phosphorothioate oligodeoxynucleotide in the skin after topical delivery by iontophoresis and electroporation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Characteristics of oligonucleotide uptake in human keratinocyte cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Flow cytometric and microscopic characterization of the uptake and distribution of phosphorothioate oligonucleotides in human keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Inhibition of interferon-gamma-induced intercellular adhesion molecule-1 expression on human keratinocytes by phosphorothioate antisense oligodeoxynucleotides is the consequence of antisense-specific and antisense-non-specific effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.1.75

21 January 2018

Identifiers

DOI

10.1517/14712598.4.1.75

1 reference

1 August 2017

1 reference